Mitchell J. Frederick
YOU?
Author Swipe
View article: Supplementary Table 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary Table 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
TP53 GOF defined using the IARC database
View article: Supplementary figure 3 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary figure 3 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
Primary tumor growth influenced by Keap1 status and tobacco carcinogen, BAP
View article: Supplementary figure 4 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary figure 4 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
Primary tumor growth influenced by Keap1 haploinsufficiency
View article: Data from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Data from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
Purpose:Alterations in the KEAP1/NFE2L2 (NRF2)/CUL3 pathway occur in ∼20% of human head and neck squamous cell carcinomas (HNSCC) and are associated with resistance to standard-of-care therapy. However, this pathway’s role in radiotherapy …
View article: Supplementary figure 7 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary figure 7 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
Nrf2 knockdown in Keap1-deficient murine HNSCC cell lines and RT responses
View article: Supplementary Materials & Methods1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary Materials & Methods1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
Detailed explanation of the experimental protocol
View article: Supplementary figure 5 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary figure 5 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
TCGA RNA sequencing analysis shows leukocyte subsets in OCSCC samples
View article: Supplementary figure 6 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary figure 6 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
Keap1 tumor growth influenced by fractionated radiation therapy
View article: Supplementary figure 2 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary figure 2 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
The status and co-occurrence of mutations in patients with HNSCC
View article: Supplementary figure 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary figure 1 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
Primary tumor growth influenced by tobacco carcinogen, BAP
View article: Supplementary Table 2 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Supplementary Table 2 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma Open
Gene list for mouse leukocyte subsets
View article: Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC
Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC Open
Purpose Cisplatin is the gold standard systemic agent for definitive treatment of HNSCC. The purpose of this study was to investigate the role of SPP1 in the progression and metastasis of cisplatin-resistant HNSCC, particularly in the cont…
View article: NOTCH1 Acts as a Tumor Suppressor That Induces Early Differentiation in Head and Neck Cancer
NOTCH1 Acts as a Tumor Suppressor That Induces Early Differentiation in Head and Neck Cancer Open
We identified frequent inactivating notch1 mutations in HNSCC over a decade ago, indicating its role as a tumor suppressor—unlike its oncogenic function in leukemias and salivary gland tumors. However, there has been much debate in the lit…
View article: Reliable RNA-seq analysis from FFPE specimens as a means to accelerate cancer-related health disparities research
Reliable RNA-seq analysis from FFPE specimens as a means to accelerate cancer-related health disparities research Open
Whole transcriptome sequencing (WTS/ RNA-Seq) is a ubiquitous tool for investigating cancer biology. RNA isolated from frozen sources limits possible studies for analysis of associations with phenotypes or clinical variables requiring long…
View article: Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting Open
Background For patients with head and neck squamous cell carcinoma (HNSCC), failure of definitive radiation combined with cisplatin nearly universally results in death. Although hyperactivation of the Nrf2 pathway can drive radiation and c…
View article: Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer
Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer Open
Purpose Exposomes are critical drivers of carcinogenesis. However, how they modulate tumor behavior remains unclear. Extensive clinical data link cigarette smoke as a key exposome that promotes aggressive tumors, higher rates of metastasis…
View article: Reliable RNA-seq analysis from FFPE specimens as a means to accelerate cancer-related health disparities research
Reliable RNA-seq analysis from FFPE specimens as a means to accelerate cancer-related health disparities research Open
Whole transcriptome sequencing (WTS/ RNA-Seq) is a ubiquitous tool for investigating cancer biology. RNA isolated from frozen sources limits possible studies for analysis of associations with phenotypes or clinical variables requiring long…
View article: Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer
Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer Open
Overall Immune infiltration at the primary site was significantly associated with clinical outcome of OSCC patients with ENE.
View article: Supp Figure 2 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Supp Figure 2 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Supp Figure 2
View article: Supplementary Tables 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Supplementary Tables 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Supplementary Tables
View article: Supp Figure 3 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Supp Figure 3 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Supp Figure 3
View article: Supp Figure 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Supp Figure 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Supp Figure 1
View article: Supp Figure 2 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Supp Figure 2 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Supp Figure 2
View article: Full Western Blot Images 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Full Western Blot Images 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Full Western Blot Images
View article: Full Western Blot Images 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Full Western Blot Images 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Full Western Blot Images
View article: Supp Figure 4 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Supp Figure 4 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Supp Figure 4
View article: Data from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Data from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Purpose:Radiation and platinum-based chemotherapy form the backbone of therapy in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). We have correlated focal adhesion kinase (FAK/PTK2) expression with radior…
View article: Supplementary Tables 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Supplementary Tables 1 from FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner Open
Supplementary Tables